Journal ArticleDOI
Promising Survival for Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concomitant Radiation Plus Temozolomide Followed by Adjuvant Temozolomide
Roger Stupp,Pierre Yves Dietrich,Sandrine Ostermann Kraljevic,Alessia Pica,Ivan Maillard,Phillipe Maeder,Reto Meuli,Robert C. Janzer,Gianpaolo Pizzolato,Raymond Miralbell,F. Porchet,Luca Regli,Nicolas de Tribolet,René O. Mirimanoff,Serge Leyvraz +14 more
Reads0
Chats0
TLDR
This regimen of concomitant chemoradiotherapy followed by adjuvant chemotherapy may prolong the survival of patients with glioblastoma.Abstract:
PURPOSE: Temozolomide is a novel oral alkylating agent with demonstrated efficacy as second-line therapy for patients with recurrent anaplastic astrocytoma and glioblastoma multiforme (GBM). This phase II study was performed to determine the safety, tolerability, and efficacy of concomitant radiation plus temozolomide therapy followed by adjuvant temozolomide therapy in patients with newly diagnosed GBM. PATIENTS AND METHODS: Sixty-four patients were enrolled onto this open-label, phase II trial. Temozolomide (75 mg/m2/d × 7 d/wk for 6 weeks) was administered orally concomitant with fractionated radiotherapy (60 Gy total dose: 2 Gy × 5 d/wk for 6 weeks) followed by temozolomide monotherapy (200 mg/m2/d × 5 days, every 28 days for six cycles). The primary end points were safety and tolerability, and the secondary end point was overall survival. RESULTS: Concomitant radiation plus temozolomide therapy was safe and well tolerated. Nonhematologic toxicities were rare and mild to moderate in severity. During t...read more
Citations
More filters
Journal ArticleDOI
Concurrent temozolomide and radiation, a reasonable option for elderly patients with glioblastoma multiforme?
Randall J. Kimple,Sarah Grabowski,Michael Papez,Frances A. Collichio,Matthew G. Ewend,David E. Morris +5 more
TL;DR: Concomitant daily temozolomide and radiation followed by adjuvant temozoomide is a tolerable and reasonable treatment option and has a good performance status for elderly patients diagnosed with glioblastoma.
Journal ArticleDOI
Convection-enhanced drug delivery for gliomas
TL;DR: To date, randomized trials of CED therapy have yet to definitely show survival advantage as compared with today's standard of care, however, early studies appear to have been limited by “first generation” delivery techniques.
Journal ArticleDOI
Phase I study of temozolomide combined with oral etoposide in children with recurrent or progressive medulloblastoma
Antonio Ruggiero,Daniela Rizzo,Giorgio Attinà,Ilaria Lazzareschi,Stefano Mastrangelo,Palma Maurizi,Roberta Migliorati,P Bertolini,Maria Pastore,Cesare Colosimo,Riccardo Riccardi +10 more
TL;DR: The combination was well tolerated and demonstrated antitumour activity and the recommended phase II dose in children is TMZ 150 mg/m(2) on days 1-5 and VP-16 50 mg/M( 2) onDays 1-10 every 28 d.
Journal ArticleDOI
Immunotherapy for malignant glioma
Carter M. Suryadevara,Terence Verla,Luis Sanchez-Perez,Elizabeth A. Reap,Bryan D. Choi,Peter E. Fecci,John H. Sampson +6 more
TL;DR: In this paper, a review of emerging immunotherapeutic platforms for the treatment of MG, focusing on the development and application of a CAR-based strategy against GBM is presented.
Journal ArticleDOI
Temozolomide: realizing the promise and potential.
Nagasubramanian R,Dolan Me +1 more
TL;DR: It is suggested that temozolomide, as currently used, has limited efficacy in treating refractory malignant infiltrative brain tumors, and survival benefit is, at best, a few weeks longer than that with procarbazine.
References
More filters
Journal ArticleDOI
Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: A cooperative clinical trial
Walker,Eben Alexander,William E. Hunt,MacCarty Cs,Mahaley Ms,John Mealey,Norrell Ha,Owens G,Joseph Ransohoff,Charles B. Wilson,Gehan Ea,Strike Ta +11 more
TL;DR: An analysis of prognostic factors indicates that the initial performance status, age, the use of only a surgical biopsy, parietal location, the presence of seizures, or the involvement of cranial nerves II, III, IV, and VI are all of significance.
Journal ArticleDOI
Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.
Walker,Sylvan B. Green,David P. Byar,Eben Alexander,Batzdorf U,Brooks Wh,William E. Hunt,MacCarty Cs,Mahaley Ms,John Mealey,Owens G,Ransohoff J nd,Robertson Jt,W. R. Shapiro,Smith Kr,Charles B. Wilson,Strike Ta +16 more
TL;DR: It is suggested that it is best to use radiotherapy in the post-surgical treatment of malignant glioma and to continue the search for an effective chemotherapeutic regimen to use in addition to radiotherapy.
Journal ArticleDOI
The new WHO classification of brain tumours.
TL;DR: The new edition of the World Health Organization (WHO) book on ‘Histological Typing of Tumours of the Central Nervous System’ reflects the progress in brain tumour classification which has been achieved since publication of the first edition in 1979.
Journal ArticleDOI
Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas
Henry Brem,Steven Piantadosi,Steven Piantadosi,Peter C. Burger,Michael D. Walker,Robert G. Selker,N. A. Vick,K Black,Michael B. Sisti,Steven Brem,G Mohr,P Muller,R Morawetz,S.C Schold +13 more
TL;DR: Interstitial chemotherapy delivered with polymers directly to brain tumours at the time of surgery seems to be a safe and effective treatment for recurrent malignant gliomas.
Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials
Walter J. Curran,Charles B. Scott,John Horton,James S. Nelson,Alan S. Weinstein,A. J. Fischbach,C. H. Chang,Marvin Rotman,Sucha O. Asbell,Robert E. Krisch,D. F. Nelson +10 more
TL;DR: This study of malignant glioma patients used a non-parametric statistical technique to examine the associations of both pretreatment patient and tumor characteristics and treatment-related variables with survival duration and permits examination of the interaction between prognostic variables not possible with other forms of multivariate analysis.
Related Papers (5)
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp,Warren P. Mason,Martin J. van den Bent,Michael Weller,Barbara Fisher,Martin J.B. Taphoorn,Karl Belanger,Alba A. Brandes,Christine Marosi,Ulrich Bogdahn,Jürgen Curschmann,Robert C. Janzer,Samuel K. Ludwin,Thierry Gorlia,Anouk Allgeier,Denis Lacombe,J. Gregory Cairncross,Elizabeth Eisenhauer,René O. Mirimanoff +18 more
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Monika E. Hegi,Annie-Claire Diserens,Thierry Gorlia,Marie-France Hamou,Nicolas de Tribolet,Nicolas de Tribolet,Michael Weller,Johan M. Kros,Johannes A. Hainfellner,Warren P. Mason,Luigi Mariani,Jacoline E C Bromberg,Peter Hau,René O. Mirimanoff,J. Gregory Cairncross,Robert C. Janzer,Roger Stupp +16 more
Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials.
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp,Monika E. Hegi,Warren P. Mason,Martin J. van den Bent,Martin J.B. Taphoorn,Robert C. Janzer,Samuel K. Ludwin,Anouk Allgeier,Barbara Fisher,Karl Belanger,Peter Hau,Alba A. Brandes,J.M.M. Gijtenbeek,Christine Marosi,Charles J. Vecht,Karima Mokhtari,Pieter Wesseling,Salvador Villà,Elizabeth Eisenhauer,Thierry Gorlia,Michael Weller,Denis Lacombe,J. Gregory Cairncross,René-Olivier Mirimanoff +23 more